• Home
  • About IonChannelCentral

Ion channel News

Entries RSS | Comments RSS
  • Tags

    agonist amitiza Amlodipine Anesiva Angiotensin II AT1 antagonist AstraZeneca ca channel Calcium Channel chloride channel CIC-2 CIC2 cl channel Clevelox Clevidipine Cleviprex CV therapeutics Icagen Ion Channel KCa3.1 K Channel Licensing lidocaine lubiprostone Merck na channel Novartis phase II Potassium Channel preclinical Regulatory Research RU-0211 RU0211 Senicapoc Sodium channel SPI-0211 Sucampo takeda The Medicines Company TRPV1 UCB Vanilloid voltage gated VR1

Dendreons TRPM8 modulator D3263 shows promise in BPH

Posted on May 21, 2008 by crimsoncanary

Dendreon’s TRPM8 modulator D-3263 has been shown to reduce prostate weight by 39% in an animal model of benign prostatic hypertrophy (BPH)

Filed under: Ion Channel | Tagged: D-3263, D3263, Dendreon, TRPM8

« Ion Channel Innovations report on gene therapy for erectile dysfunction FDA accepts Zingo (lidocaine) sNDA for needle associated pain »

Leave a Reply

Click here to cancel reply.

  • Calendar

    • May 2008
      M T W T F S S
      « Apr   Jun »
       1234
      567891011
      12131415161718
      19202122232425
      262728293031  
  • Blogroll

    • CrimsonCanary.com
    • IonChannelCentral
    • KinaseCentral
    • PharmaCompanyPipelines

Blog at WordPress.com. Theme: Digg 3 Column by WP Designer